Growing community of inventors

Tianjin, China

Genbei Wang

Average Co-Inventor Count = 10.29

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 0

Genbei WangXiaohui Ma (2 patents)Genbei WangShunnan Zhang (1 patent)Genbei WangShuiping Zhou (1 patent)Genbei WangJian Li (1 patent)Genbei WangZhixin Guo (1 patent)Genbei WangChen Chen (1 patent)Genbei WangXiaodan Cao (1 patent)Genbei WangLihua Zhang (1 patent)Genbei WangLulu Yan (1 patent)Genbei WangJing Li (1 patent)Genbei WangSen Lin (1 patent)Genbei WangGuoyong Jia (1 patent)Genbei WangRuijing Huang (1 patent)Genbei WangYuanyuan Wang (1 patent)Genbei WangHenry Sun (1 patent)Genbei WangJun Han (1 patent)Genbei WangPing Tai (1 patent)Genbei WangYongjie Jin (1 patent)Genbei WangGenbei Wang (2 patents)Xiaohui MaXiaohui Ma (15 patents)Shunnan ZhangShunnan Zhang (17 patents)Shuiping ZhouShuiping Zhou (8 patents)Jian LiJian Li (8 patents)Zhixin GuoZhixin Guo (6 patents)Chen ChenChen Chen (4 patents)Xiaodan CaoXiaodan Cao (3 patents)Lihua ZhangLihua Zhang (2 patents)Lulu YanLulu Yan (2 patents)Jing LiJing Li (2 patents)Sen LinSen Lin (1 patent)Guoyong JiaGuoyong Jia (1 patent)Ruijing HuangRuijing Huang (1 patent)Yuanyuan WangYuanyuan Wang (1 patent)Henry SunHenry Sun (1 patent)Jun HanJun Han (1 patent)Ping TaiPing Tai (1 patent)Yongjie JinYongjie Jin (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Tasly Pharmaceutical Group Co., Ltd. (1 from 35 patents)

2. Tasly Biopharmaceuticals Co., Ltd. (1 from 2 patents)


2 patents:

1. 12152059 - Method of treating nash using a long-acting mutant human fibroblast growth factor

2. 9889093 - Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/27/2025
Loading…